MapLight Schizophrenia Drug Progress
MapLight Therapeutics' ML-007C-MA Shows Significant Improvement in Schizophrenia Phase 2 Trial
Anonymous
Key Points
1
Topline ZEPHYR results show a PANSS total effect size of 0.37 at the 210/3 mg bid dose, increasing to 0.50 among participants who completed the full treatment, with a cognitive benefit that may be independent of symptom reduction.
2
Insider activity data indicate roughly 22.8 million dollars in MPLT shares sold over the past three months, signaling potential concerns among insiders.
3
Analyst coverage highlights a Buy rating with a 43 target on MPLT from TipRanks, while Spark AI Analyst rates Neutral and flags ongoing losses, cash burn, and governance changes that could affect funding/dilution risk.
4
MapLight’s market capitalization is noted around 1.66 billion, providing context for potential dilution risk despite the observed clinical signal.
MapLight Therapeutics' experimental schizophrenia drug, ML-007C-MA, delivered a split verdict from its Phase 2 ZEPHYR trial — sending shares down 55% in premarket trading after one dosing regimen failed, while a separate twice-daily dose hit its primary goal, according to Reuters and Yahoo Finance.
The drug is a combination of betovumeline and fesoterodine. The once-daily dose of 330/6 mg failed to show statistically significant symptom improvement in adults with acute schizophrenia, Reuters reported. But the twice-daily dose of 210/3 mg told a different story.
Twice-Daily Dose Hits Primary Goal With Cognitive Bonus
The 210/3 mg twice-daily dose met the trial's primary endpoint. It produced statistically significant improvements in PANSS total scores — a standard measure of schizophrenia symptoms. The effect size was 0.37 across all participants. Among those who completed the full treatment period, it rose to 0.50, a more meaningful result.
Beyond symptom relief, the drug showed a notable cognitive benefit. Researchers believe this improvement may be independent of symptom reduction — meaning the drug could help patients think more clearly even apart from easing psychosis. The safety profile was clean, with low dropout rates and no major metabolic or anticholinergic side effects, according to Yahoo Finance.
Once-Daily Failure Spooked Investors Despite Positive Signals
The once-daily regimen's failure hit investors hard. Shares of MapLight — ticker MPLT — plunged 55% in premarket trading, according to Reuters. The selloff highlights how a single dosing arm can overshadow positive results from another arm of the same trial.
MapLight's market cap sits around $1.66 billion. Despite the stock drop, the company plans to run an additional pivotal trial to support potential drug registration. MapLight will also hold an investor conference to walk through ZEPHYR results and outline next development steps.
Analysts Split on Buy Rating Versus Cash Burn Risk
Analyst views on MPLT are divided. TipRanks carries a Buy rating with a $43 price target on the stock. But Spark AI Analyst rates it Neutral, pointing to ongoing losses, cash burn, and recent governance changes that could lead to dilution — meaning new shares issued that shrink existing investors' stakes.
Insider activity adds a cautionary note. Over the past three months, insiders sold roughly $22.8 million worth of MPLT shares. That level of selling by company insiders can signal concern about near-term prospects, even as the clinical data showed some progress, according to Yahoo Finance.
MapLight Charts Path Toward Registration With New Pivotal Trial
Despite the mixed results, MapLight is pressing forward. The company says the twice-daily arm's data is strong enough to justify another pivotal trial — the kind of large, definitive study regulators require before approving a drug. The favorable safety profile, with no major metabolic side effects, strengthens that case.
Schizophrenia remains a huge unmet need. Existing drugs often carry heavy side effects, including weight gain and metabolic problems. A drug with a clean safety profile and potential cognitive benefits could stand out — if MapLight can fund the next trial without excessive dilution to current shareholders, according to Reuters.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
21
Articles
101
Reach
122
A
AnonymousAuthor
